FDA to discuss imatinib for PAH
12:33 EDT 20 Jul 2012 | BioCentury
FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Sept. 14 to discuss an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for imatinib to treat pulmonary arterial hypertension (PAH). The PDUFA date is not disclosed. Novartis submitted the..
Original Article: FDA to discuss imatinib for PAH
More From BioPortfolio on "FDA to discuss imatinib for PAH"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
